BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Jaguar Health (JAGX)Jaguar HealthConference / presentation

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at

Related news

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-04-10 00:15 EST

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

HROWHarrow, Inc.2026-03-18 11:00 EST

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

VIRXViracta Therapeutics2024-09-05 15:32 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SCYXSCYNEXIS2026-08-10 20:30 EST

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

IBRXImmunityBio2026-08-10 13:00 EST

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-08-18 13:00 EST

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

JAGXJaguar Health2026-08-05 13:00 EST

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

JAGXJaguar Health2026-07-28 13:00 EST

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

JAGXJaguar Health2026-07-22 13:00 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

JAGXJaguar Health2026-06-30 13:00 EST

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Stock data

Close
0.88 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California